Custom antibody development

We offer world-leading antibody development platforms based on a proprietary RabMAb® rabbit monoclonal platform, a phase display platform (AxioMx), and a next-generation sequencing platform (NGS-RabMAb®)

This product is an IgG fraction antibody purified from monospecific antiserum by a multi-step process including delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against buffer.

Applications

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application

Abreviews

Notes

Flow Cyt

Use at an assay dependent concentration. (PMID 20147632)

ab200208-Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.

Dot blot

Use at an assay dependent concentration.

ELISA

Use at an assay dependent concentration.

This antibody has been assayed against 1.0µg of Adenosine Deaminase in a standard capture ELISA using Peroxidase conjugated streptavidin and ABTS (2,2'-azino-bis-[3-ethylbenthiazoline-6-sulfonic acid]) as a substrate for 30 minutes at RT.

Immunomicroscopy

Use at an assay dependent concentration.

Target

Function

Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4. Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion.

Tissue specificity

Found in all tissues, occurs in large amounts in T-lymphocytes and, at the time of weaning, in gastrointestinal tissues.

Involvement in disease

Defects in ADA are the cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-negative due to adenosine deaminase deficiency (ADASCID) [MIM:102700]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. ADA-SCID is an autosomal recessive form accounting for about 50% of non-X-linked SCIDs. ADA deficiency has been diagnosed in chronically ill teenagers and adults (late or adult onset). Population and newborn screening programs have also identified several healthy individuals with normal immunity who have partial ADA deficiency.

Thank you for your enquiry and your interest in our products.
According to the datasheets, ab54969 has not been tested for ELISA (only WB, Flow Cytmetry); whilst the other antibody (ab34677) has been characterized for indirect ELISA system. Unfor...

Thank you for your patience while I investigated the source of the note on our datasheet that specified the molecular weight of ADA as 104 kDa.
The predicted molecular weight should be given as 40.7 kDa, based on the UniProt database entry:
...